Pharmacopuncture for Cancer Care: A Systematic Review

Table 5

Reported AEs in the included studies.

Author; Sample Size* (Int./Cont.)	Condition	Intervention group	Control group
Reported “No AEs” for intervention group
Liu et al. 2011 [24]	CINV	No AEs occurred	No AEs occurred
Yang et al. 2011 [25]	CINV	No AEs occurred	NR
Chen 2007 [27]	CINV	No AEs occurred	NR
Xue 2005 [37]	QOL	No AEs occurred	NR
Shen 2009 [18]; 23/25	Pain	No AEs occurred	Constipation (9), nausea and vomiting (6), dizziness (3)
Identical Drug Used for Both Groups
Liu 2010 [16]; 28/19	Pain	Nausea and vomiting (1), headache and dizziness (2); Resolved after the end of treatment	Nausea and vomiting (3), headache and dizziness (5), drowsiness and fatigue (2); Resolved after the end of treatment
Sui and Zhang 2009 [33]; 25/22	Hiccup	Xerostomia (9); Resolved after the end of treatment	Xerostomia (10); Resolved after the end of treatment
Tao et al. 2000 [29]**; 160/160	CINV	Headache and dizziness (26), bloating and constipation (4), and diarrhea (6); Resolved after the end of treatment	Headache and dizziness (33), bloating and constipation (9), and diarrhea (20); Resolved after the end of treatment
Yan et al. 1997 [36]; 28/30	Fever	Local pain and limitation of lower limb movement (5); Resolved after the end of treatment	Insomnia and increased talkativeness (8) and panhidrosis (2); Did not affect further treatment
Different Drugs Used for Each Groups
Wang et al. 2004a*** [20]	Pain	Xerostomia, hot flashes, and blurred vision; Relieved spontaneously	Nausea, vomiting, constipation, and urinary retention; Mild and tolerable level
Wang et al. 2004b*** [21]	Pain	Xerostomia, hot flashes, and blurred vision; Relieved spontaneously; Temporary low blood sugar; Continued treatment after glucose IV injection or a meal	Nausea, vomiting, constipation, and urinary retention; Mild and tolerable level
Tao et al. 2000 [29]**; 160/160	CINV	Headache and dizziness (26), bloating and constipation (4), and diarrhea (6); Resolved after the end of treatment	Headache and dizziness (29), bloating and constipation (22), and diarrhea (5); Resolved after the end of treatment

AEs: adverse events; CINV: chemotherapy-induced nausea and vomiting; Cont.: control group; Int.: intervention group; IV: intravenous; NR: not reported; QOL: quality of life.
Number in the parenthesis is reported number of cases.
*Sample size is reported on this table for studies with numerical data only.
**Two different control groups yielded two separate documentations in this table.
***Number of cases for symptoms were not reported.